BXP:LSE-Beximco Pharmaceuticals Limited (GBX)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | LSE

Last Closing Price

GBX 90.00

Change

+0.50 (+0.56)%

Market Cap

GBX 0.57B

Volume

0.16M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients in Bangladesh. The company offers allergic disorder, analgesic and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It provides its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was founded in 1976 and is headquartered in Dhaka, Bangladesh.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-25 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
HIK:LSE Hikma Pharmaceuticals PLC

+1.00 (+0.04%)

GBX5.99B 16.61 9.92
INDV:LSE Indivior PLC

-4.30 (-3.31%)

GBX0.96B 3.30 1.17
APH:LSE Alliance Pharma plc

-0.40 (-0.54%)

GBX0.40B 35.84 12.39
BMK:LSE Benchmark Holdings plc

+0.25 (+0.45%)

GBX0.37B N/A 40.96
AMYT:LSE Amryt Pharma plc

-1.00 (-0.50%)

GBX0.33B N/A N/A
EAH:LSE ECO Animal Health Group plc

-7.50 (-3.03%)

GBX0.17B 18.91 9.81
STX:LSE Shield Therapeutics plc

-3.00 (-2.65%)

GBX0.14B 53.33 190.85
AGY:LSE Allergy Therapeutics plc

-1.00 (-6.06%)

GBX0.11B 14.76 5.96
VLG:LSE Venture Life Group plc

N/A

GBX0.08B 30.55 15.16
DNL:LSE Diurnal Group plc

+0.50 (+0.97%)

GBX0.07B N/A N/A

ETFs Containing BXP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 95.65% 69% D+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.65% 69% D+ 95% A
Trailing 12 Months  
Capital Gain 104.55% 69% D+ 96% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 104.55% 69% D+ 95% A
Trailing 5 Years  
Capital Gain 329.55% 91% A- 96% A
Dividend Return 31.83% 100% A+ 88% B+
Total Return 361.38% 91% A- 95% A
Average Annual (5 Year Horizon)  
Capital Gain 25.38% N/A N/A 85% B
Dividend Return 3.61% N/A N/A 76% C
Total Return 28.99% N/A N/A 85% B
Risk Return Profile  
Volatility (Standard Deviation) 64.61% N/A N/A 17% F
Risk Adjusted Return 44.87% N/A N/A 59% F
Market Capitalization 0.57B 86% B 74% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 11.71 88% B+ 65% D
Price/Book Ratio 1.12 100% A+ 57% F
Price / Cash Flow Ratio 0.10 50% F 65% D
EV/EBITDA 0.07 100% A+ 99% A+
Management Effectiveness  
Return on Equity 11.63% 83% B 76% C
Return on Invested Capital 10.33% 71% C- 72% C-
Return on Assets 7.04% 92% A- 86% B
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.41 77% C+ 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector